Pseudomonas aeruginosa Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Pseudomonas aeruginosa Infections – Pipeline Review, H2 2019’, provides an overview of the Pseudomonas aeruginosa Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections

– The report reviews pipeline therapeutics for Pseudomonas aeruginosa Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Pseudomonas aeruginosa Infections therapeutics and enlists all their major and minor projects

– The report assesses Pseudomonas aeruginosa Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pseudomonas aeruginosa Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acies Bio doo

Affilogic SAS

Affinivax Inc

Agile Sciences Inc

AGILeBiotics BV

AiCuris GmbH & Co KG

Akthelia Pharmaceuticals Ltd

AlgiPharma AS

Amicrobe Inc

AMR Centre Ltd

Appili Therapeutics Inc

Aridis Pharmaceuticals Inc

Armata Pharmaceuticals Inc

AstraZeneca Plc

Atterx Biotherapeutics Inc

Aurora Oncology Inc

Biolytics Pharma

Biolytx Pharmaceuticals Corp

Biomendics LLC

BlueWillow Biologics Inc

Boston Pharmaceuticals Inc

Bugworks Research India Pvt Ltd

Catabasis Pharmaceuticals Inc

Centauri Therapeutics Ltd

Combioxin SA

ContraFect Corp

CSA Biotechnologies LLC

Cyclacel Pharmaceuticals Inc

Destiny Pharma Plc

Eligochem Ltd

EnBiotix Inc

Entasis Therapeutics Inc

Evaxion Biotech ApS

Evotec SE

F. Hoffmann-La Roche Ltd

Fedora Pharmaceuticals Inc

Forge Therapeutics Inc

Helix BioMedix Inc

Hsiri Therapeutics LLC

Immun System IMS AB

Inhibrx Inc

Insmed Inc

KBP BioSciences Co Ltd

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

Linnaeus Bioscience Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Mid-Atlantic BioTherapeutics, Inc.

Neem Biotech Ltd

Neoculi Pty Ltd

New Amsterdam Sciences Inc

Nosopharm SAS

Novabiotics Ltd

Oryn Therapeutics

Peptilogics Inc

Pfizer Inc

Pharmaero ApS

Pherecydes Pharma SA

Phico Therapeutics Ltd

PlumeStars Srl

Procarta Biosystems Ltd

Qpex Biopharma Inc

Redx Pharma Plc

RemAb Therapeutics SL

SciBac Inc

Sealife PHARMA GMBH

Sequoia Sciences Inc

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

TAXIS Pharmaceuticals Inc

Tetraphase Pharmaceuticals Inc

VenatoRx Pharmaceuticals Inc

Venus Medicine Research Center

Visterra Inc

Wockhardt Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Pseudomonas aeruginosa Infections - Overview 7

Pseudomonas aeruginosa Infections - Therapeutics Development 8

Pseudomonas aeruginosa Infections - Therapeutics Assessment 25

Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 33

Pseudomonas aeruginosa Infections - Drug Profiles 57

Pseudomonas aeruginosa Infections - Dormant Projects 244

Pseudomonas aeruginosa Infections - Discontinued Products 249

Pseudomonas aeruginosa Infections - Product Development Milestones 250

Appendix 262

List of Tables

“List of Tables

Table 1: Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Universities/Institutes, H2 2019

Table 7: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 8: Products under Development by Companies, H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 14: Products under Development by Universities/Institutes, H2 2019

Table 15: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 16: Number of Products by Stage and Target, H2 2019

Table 17: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 18: Number of Products by Stage and Mechanism of Action, H2 2019

Table 19: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 20: Number of Products by Stage and Route of Administration, H2 2019

Table 21: Number of Products by Stage and Molecule Type, H2 2019

Table 22: Pseudomonas aeruginosa Infections – Pipeline by Acies Bio doo, H2 2019

Table 23: Pseudomonas aeruginosa Infections – Pipeline by Affilogic SAS, H2 2019

Table 24: Pseudomonas aeruginosa Infections – Pipeline by Affinivax Inc, H2 2019

Table 25: Pseudomonas aeruginosa Infections – Pipeline by Agile Sciences Inc, H2 2019

Table 26: Pseudomonas aeruginosa Infections – Pipeline by AGILeBiotics BV, H2 2019

Table 27: Pseudomonas aeruginosa Infections – Pipeline by AiCuris GmbH & Co KG, H2 2019

Table 28: Pseudomonas aeruginosa Infections – Pipeline by Akthelia Pharmaceuticals Ltd, H2 2019

Table 29: Pseudomonas aeruginosa Infections – Pipeline by AlgiPharma AS, H2 2019

Table 30: Pseudomonas aeruginosa Infections – Pipeline by Amicrobe Inc, H2 2019

Table 31: Pseudomonas aeruginosa Infections – Pipeline by AMR Centre Ltd, H2 2019

Table 32: Pseudomonas aeruginosa Infections – Pipeline by Appili Therapeutics Inc, H2 2019

Table 33: Pseudomonas aeruginosa Infections – Pipeline by Aridis Pharmaceuticals Inc, H2 2019

Table 34: Pseudomonas aeruginosa Infections – Pipeline by Armata Pharmaceuticals Inc, H2 2019

Table 35: Pseudomonas aeruginosa Infections – Pipeline by AstraZeneca Plc, H2 2019

Table 36: Pseudomonas aeruginosa Infections – Pipeline by Atterx Biotherapeutics Inc, H2 2019

Table 37: Pseudomonas aeruginosa Infections – Pipeline by Aurora Oncology Inc, H2 2019

Table 38: Pseudomonas aeruginosa Infections – Pipeline by Biolytics Pharma, H2 2019

Table 39: Pseudomonas aeruginosa Infections – Pipeline by Biolytx Pharmaceuticals Corp, H2 2019

Table 40: Pseudomonas aeruginosa Infections – Pipeline by Biomendics LLC, H2 2019

Table 41: Pseudomonas aeruginosa Infections – Pipeline by BlueWillow Biologics Inc, H2 2019

Table 42: Pseudomonas aeruginosa Infections – Pipeline by Boston Pharmaceuticals Inc, H2 2019

Table 43: Pseudomonas aeruginosa Infections – Pipeline by Bugworks Research India Pvt Ltd, H2 2019

Table 44: Pseudomonas aeruginosa Infections – Pipeline by Catabasis Pharmaceuticals Inc, H2 2019

Table 45: Pseudomonas aeruginosa Infections – Pipeline by Centauri Therapeutics Ltd, H2 2019

Table 46: Pseudomonas aeruginosa Infections – Pipeline by Combioxin SA, H2 2019

Table 47: Pseudomonas aeruginosa Infections – Pipeline by ContraFect Corp, H2 2019

Table 48: Pseudomonas aeruginosa Infections – Pipeline by CSA Biotechnologies LLC, H2 2019

Table 49: Pseudomonas aeruginosa Infections – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019

Table 50: Pseudomonas aeruginosa Infections – Pipeline by Destiny Pharma Plc, H2 2019

Table 51: Pseudomonas aeruginosa Infections – Pipeline by Eligochem Ltd, H2 2019

Table 52: Pseudomonas aeruginosa Infections – Pipeline by EnBiotix Inc, H2 2019

Table 53: Pseudomonas aeruginosa Infections – Pipeline by Entasis Therapeutics Inc, H2 2019

Table 54: Pseudomonas aeruginosa Infections – Pipeline by Evaxion Biotech ApS, H2 2019

Table 55: Pseudomonas aeruginosa Infections – Pipeline by Evotec SE, H2 2019

Table 56: Pseudomonas aeruginosa Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Table 57: Pseudomonas aeruginosa Infections – Pipeline by Fedora Pharmaceuticals Inc, H2 2019

Table 58: Pseudomonas aeruginosa Infections – Pipeline by Forge Therapeutics Inc, H2 2019

Table 59: Pseudomonas aeruginosa Infections – Pipeline by Helix BioMedix Inc, H2 2019

Table 60: Pseudomonas aeruginosa Infections – Pipeline by Hsiri Therapeutics LLC, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports